RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

http://www.wikidata.org/entity/Q33306326

about

Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Synthetic protection short interfering RNA screen reveals glyburide as a novel radioprotector.Small interfering RNA screen for phosphatases involved in IgE-mediated mast cell degranulation.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance JAK Kinases in Health and Disease: An Update Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.Specific Jak3 Downregulation in Lymphocytes Impairs γc Cytokine Signal Transduction and Alleviates Antigen-driven Inflammation In Vivo Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia RNAi screen for rapid therapeutic target identification in leukemia patients.Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability.Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.Identification of new possible targets for leukemia treatment by kinase activity profiling.FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens.RNAi Screening of Leukemia Cells Using Electroporation FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.

P2860

Q24313261-849ADD20-C31C-4095-B561-E0BB3B86B65D Q27317150-D8DCD27F-E380-4969-92C7-28840A530EB6 Q28271752-E0F41B42-ED7F-410A-AD19-841726F0272C Q30275229-4663A01B-3B89-4A0B-9B0D-C7B7BD3B0510 Q33505771-C41D2B6A-195A-4326-9ECF-5EEA5F18E72F Q33581708-FD454863-FEC6-40F4-A9F6-455F51F592B1 Q33602552-56998454-1A81-40BA-BDC9-94F627B986D2 Q33674238-ABCDF667-EB5C-4FE9-AA31-C920295A4BB5 Q33944270-D30A7CA7-C0FC-4A0A-9548-05E0140E6D9A Q34081636-81C270D5-F286-4B57-BF79-77CDB92497F1 Q34307423-568C866F-59F6-40AA-8143-46FE881C9C88 Q34654334-70A8600A-3856-468B-9F46-D104EECE1B4E Q35072638-228B3819-E39F-45B2-8AF6-2B517E193577 Q35143027-D50F0CB6-3601-4FF3-A29F-470232AA5ECC Q36285745-16970B31-227B-44B8-BDEB-E1D3B92E3D6D Q36291648-A610324B-FEAC-4893-AE6B-2B6FA3F2DA0D Q36299372-37383D6E-6C83-4EC8-BA2E-A98A8B04CDF0 Q36406203-D975E923-E3EF-4009-AA8C-B33568BB1981 Q36836799-EF553FDD-E2F1-4A5B-BD44-C2AA9D481A14 Q37187716-7281EC12-9387-4B13-8182-DD9C565ED21B Q37623532-863F0155-727C-4480-9841-89B926735328 Q37687519-63B28F6F-4727-4CEF-98F0-B57412A9AD83 Q38727999-700B13AF-B3E1-4738-9C97-2D19535DFABE Q38969204-71CB5FD7-E7FD-4A39-9C7E-3112416783AC Q39100525-B65BB925-B137-4CCE-A750-AA1CAF661F64 Q39137990-6ED22654-9B6B-4FC6-90A2-D5D69AEF72BC Q39623499-CDEECE40-5FF6-4B9A-99A1-E8F916A29298 Q39626383-1233625A-2453-4FF0-8592-FA223BF07400 Q41459669-35FB29CC-988D-4D2F-8B81-ED34F56856C7 Q41860715-9A4BEFC8-B34B-4CD8-B295-78A3DCA0C30A Q42132650-C1216EBA-B7FA-49F2-8B06-0A77F46F342B Q43238541-C398CAC9-5E73-4FF4-A7B9-38679A373430 Q47144472-E5880D19-F167-4495-8C33-EA487756BB1C Q54524656-3B2C6774-1613-4D57-B34B-185E326C2F05

P2860

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

http://www.wikidata.org/entity/Q33306326

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@ast

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@en

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@nl

type

label

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@ast

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@en

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@nl

prefLabel

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@ast

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@en

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@nl

P1433

Q33306326-79BB1B70-A31E-4A0B-AAA0-9578A854D42E

P1476

Q33306326-3B8D0E93-5EB2-4ED1-B648-50DE0B05A1E6

P2093

Q33306326-12566CC8-4774-44F3-A589-804E903D4B92

Q33306326-3A93D02D-EAED-4ABC-B6A2-A30116EA206B

Q33306326-43CD5AF9-13B6-4ABE-8AAB-01401665F0A7

Q33306326-5DEECCD1-09FD-47F4-A284-EC34B95CAAE4

Q33306326-881752E0-D1EF-4620-B41A-7089A8618B39

Q33306326-BCE5E95A-DCF3-4A88-9471-25EAD0646920

Q33306326-D4892564-DE1D-44F8-AC47-2B5E45FE8736

Q33306326-D9A5366B-FA36-467A-AF6C-AAB3ED7D6152

Q33306326-E6FD0ED4-1B7F-4606-AC39-1A0F0CD371B1

P2860

Q33306326-097C2D83-FF38-429F-A886-9AE86A903825

Q33306326-0D799C52-AC11-4859-8C25-49F960C120ED

Q33306326-11B3CB6C-1819-4727-A985-0EA9CFF5D61B

Q33306326-138F7D1A-6875-4FB0-B6FF-52DF5E3A7D15

Q33306326-1785821B-8A0A-4A57-B32C-5EEA4FE4F33A

Q33306326-1800E86B-EE1A-4767-A1A1-591C83480D34

Q33306326-2649629E-EDD8-46B6-9A17-37BBFA50B115

Q33306326-2709417A-85C9-4AEC-98F7-C41D52351B0C

Q33306326-2A2702B7-A089-4FD2-BDEC-70C1A8D8D327

Q33306326-2B194737-73AE-4B12-81C0-C2375774171B

P304

Q33306326-FCF47B9C-7E9B-48A1-AEE5-905057B42E1D

P31

Q33306326-D7B090F1-8A7C-4A49-BC2E-659B26371795

P356

Q33306326-6D55DC10-4C48-48F6-ADA3-640F2DC2EA95

P407

Q33306326-B8C68369-F104-4526-8D3C-FB99CC61885A

P433

Q33306326-9BA4E062-67A6-4E75-B743-D78E5ED7ABC8

P478

Q33306326-07627A0D-6D7F-4B3F-86B7-4CB096434B95

P50

Q33306326-3A9D44E1-1776-4A9E-8B8A-598ED0F8AF1C

Q33306326-9D8E9578-3CFB-43CC-B357-814D07E82BB7

Q33306326-C6E8652F-7ECC-48D3-A14C-631C76891325

P577

Q33306326-6FC3F58B-4D84-4731-85F6-4CBE5A12BB7B

P5875

Q33306326-0CF367C4-6FCE-427A-8774-0B8636D33791

P698

Q33306326-663DD616-9C96-44DA-A383-783E66B7AEF8

P921

Q33306326-83030349-5180-4EF4-9E9A-E0A54D87EC34

Q33306326-D90A9DCB-155F-4DEB-83DB-F342111D90B1

P932

Q33306326-9EBC1E4D-9A73-4BF8-A7A3-844BD1AE7FB7

P356

BLOOD-2007-06-097253

P1433

P1476

RNAi screening of the tyrosine ...... ets in acute myeloid leukemia.

@en

P2093

Amie S Corbin

http://www.w3.org/2001/XMLSchema#string

Denise K Walters

http://www.w3.org/2001/XMLSchema#string

Heidi Erickson

http://www.w3.org/2001/XMLSchema#string

Jason Oost

http://www.w3.org/2001/XMLSchema#string

Marc Loriaux

http://www.w3.org/2001/XMLSchema#string

Mary Luttropp

http://www.w3.org/2001/XMLSchema#string

Michael W Deininger

http://www.w3.org/2001/XMLSchema#string

Stephanie G Willis

http://www.w3.org/2001/XMLSchema#string

Thomas O'Hare

http://www.w3.org/2001/XMLSchema#string

P2860

The Janus kinases (Jaks)

Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor

The role of FLT3 in haematopoietic malignancies

A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

The consensus coding sequences of human breast and colorectal cancers

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

2238-2245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-06-097253

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Brian J. Druker

Michael C. Heinrich

Jeffrey W. Tyner

P577

2007-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5822381

http://www.w3.org/2001/XMLSchema#string

P698

18025156

http://www.w3.org/2001/XMLSchema#string

P921

P932

2234058

http://www.w3.org/2001/XMLSchema#string